Week in Review: Ascletis In-Licenses China Rights to RNAi Cancer Drug
Ascletis Pharma, a US-China JV, in-licensed China rights to an innovative RNAi drug candidate from Alnylam Pharma; Yunnan Walvax expanded beyond its vaccine portfolio by obtaining a 51% stake in Shanghai Fengmao Biotech; HAO Capital of Beijing and TCL Group formed a high-end diagnostic imaging JV; Siegfried Holding, a Swiss CMO, is building an API and intermediates production facility in Nantong; Oculus received SFDA approval for Microcyn® Hydrogel, a topical wound treatment; and the SFDA has issued new regulations governing the purity and safety of excipients. More details…. Stock Symbols: (NSDQ: ALNY) (SHE: 300142) (SIX: SFZN) (NSDQ: OCLS) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});  
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here